Targeting the ubiquitin-proteasome route
HMB (beta-hydroxy beta-methylbutyrate) is a metabolite of the amino acid leucine. Its signature mechanism is defensive rather than constructive: it appears to suppress the ubiquitin-proteasome system, the cellular machinery that tags worn or surplus proteins with ubiquitin and feeds them into the proteasome for breakdown. By dampening this tagging-and-degradation cycle, HMB is positioned as a brake on muscle protein breakdown.
When the defence matters most
Because the effect is anti-catabolic, HMB tends to look most useful in situations where breakdown is elevated: caloric deficits, illness, immobilisation, ageing-related muscle loss, or unaccustomed heavy training. In well-fed, trained athletes whose breakdown is already controlled, the measurable benefit is smaller and the evidence more mixed. HMB also has weaker support for stimulating new muscle growth than for protecting existing muscle.
HMB is not a treatment for muscle-wasting diseases, which require medical management. This is general educational information, not medical advice; consult a qualified professional for clinical muscle loss.